Whitepaper

Expert interview: cancer resistance to immunotherapy

cancerresistance512

Although every cancer patient has the ability to respond to immunotherapy, tumors often fail to regress due to either primary or acquired resistance.

In our interview, Dr. Siwen Hu-Lieskovan, PhD, MD, Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah discussed the mechanisms behind immune evasion and how this understanding can help create a personalized treatment strategy with the goal of prolonged survival.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Expert interview: cancer resistance to immunotherapy

Download Whitepaper